Evaluating antibody pharmacokinetics as prerequisite for determining true efficacy as shown by dual targeting of pd-1 and cd96

HIGHLIGHTS

• who: Christina Boch and colleagues from the Boehringer Ingelheim Pharma GmbH and CoKG, Biberach an der Riss, Germany Institute of Virology, Medical University Innsbruck, Innsbruck, Austria have published the Article: Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96, in the Journal: Biomedicines 2022, 2146 of /2022/
• what: The authors show that anti-PD-1 significantly decreased tumor growth, and that anti-CD96 further increased the therapeutic benefit; meanwhile, anti-CD96 alone had no effect. The authors show that without such measurements, pharmacodynamic data cannot . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.